Clinical pathway for patients with Chronic Myeloid Leukaemia: The Euriclea Project

Clinical pathway for patients with Chronic Myeloid Leukaemia: The Euriclea Project

Authors

  • Stefano Botti Arcispedale Santa Maria Nuova-IRCCS, Reggio Emilia, Italy
  • Gianpaolo Gargiulo Federico II University Hospital of Naples, Italy
  • Felice Bombaci AIL Patients group CML, Rome, Italy
  • Giovanna Artioli Arcispedale Santa Maria Nuova-IRCCS, Reggio Emilia, Italy
  • Chiara Cosentino Department of Medicine and Surgery, University of Parma, Italy
  • Adriana Concetta Pignatelli Regina Elena National Cancer Institute of Rome, Italy
  • Daniela Torino University Hospital Careggi of Firenze, Italy
  • Maria Marcella Lionetti University Hospital Città della Salute e della Scienza of Turin, Italy
  • Emanuela Samarani University Hospital Città della Salute e della Scienza of Turin, Italy
  • Lorella Cappucciati Guglielmo da Saliceto Hospital of Piacenza, Italy
  • Paola Bordiga Spedali Civili of Brescia Hospital, Italy
  • Antonella Diodati Santo Spirito Hospital of Pescara, Italy
  • Cristiana Caffarri Italian Nurses Federation IPASVI, Rome, Italy
  • Irene Rosini Italian Nurses Federation IPASVI, Rome, Italy
  • Fabrizio Pane Federico II University Hospital of Naples, Italian Society of Hematology President, Italy

Keywords:

clinical pathways, chronic myeloid leukaemia, tirosine chinase inhibitors, nursing, proactive care, adherence, patient empowerment, side effects, adverse events

Abstract

Background and aims: The use of Tirosine Kinase Ihnibitors (TKIs) for the treatment of Chronic Myeloid Leukemia (CML) has definitely represented a turning point in the treatment of the onco-hematological diseases. Over the years, the interest of physicians, nurses, patients and caregivers has increasingly focused on the aspects of the humanization of care, the management of side effects and on the full and constant therapeutic adherence. The aim of the project was to define patient-oriented care processes, based on a proactive approach that can fully respond to the new health needs of CML patients. Methods: A nursing expert Working Group (WG) was established. WG reviewed literature about CML patients assistance and then it was conducted a survey on organizational models for the treatment of CML patients, adopted by Italian haematologic and transplant centers.  Finally, the main issues regarding CML patients care were identified and discussed on a multiprofessional basis. Results: Euriclea Project for care of CML patients with the description of a new and expanded nurse role was defined. The Nurse Case Manager or Nursing Clinical Experts were identified as key people for the management of the side effects of treatment, the promotion of the therapeutic adherence and the evaluation of efficacy and effectiveness of the process through the identification of specific indicators for structure, process and outcome. Discussion: The focal areas of the care process were identified so as to define a different approach to the CML patient, through a holistic view of care and the multidisciplinary interventions. 

Downloads

Published

18-07-2017

Issue

Section

Original article: On the patient's side: focus on leukaemia

How to Cite

1.
Clinical pathway for patients with Chronic Myeloid Leukaemia: The Euriclea Project. Acta Biomed [Internet]. 2017 Jul. 18 [cited 2024 Jun. 20];88(3 -S):5-12. Available from: https://mattioli1885journals.com/index.php/actabiomedica/article/view/6608

Most read articles by the same author(s)

1 2 3 4 5 6 7 8 9 10 11 12 13 > >>